ACER
Acer Therapeutics, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Acer Therapeutics, Inc. is a pharmaceutical company. The firm engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes Edsivo and ACER-001. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded by Christopher Schelling on September 19, 2017 and is headquartered in Newton, MA.
Market Cap: 19.1 Million
Primary Exchange: NASDAQ
Website: http://www.acertx.com
Shares Outstanding: 10.1 Million
Float: 7.53 Million
Dividend: (%)
Beta: 1.58665575434975
Sector: Health Technology
Industry: Pharmaceuticals: Major
Ethical Flags
Longest drawdown: 1817 trading days
From: 2013-02-05 To: 2020-03-30
Lowest Point:
Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date
via: SeekingAlpha at 2019-06-11 12:00:30:000
Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...
Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date
via: SeekingAlpha at 2019-06-11 12:00:30:000
Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...
Acer Therapeutics: Concerns Prior To Upcoming PDUFA Date
via: SeekingAlpha at 2019-06-11 12:00:30:000
Acer Therapeutics Inc. (ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts, focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening orphan or ultra-orphan diseases with significant unmet… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2017-09-21 | 10.355527 | 1.0 | 10.355527 | |||
| 2015-09-29 | 8.0 | 1.0 | 8.0 |